[go: up one dir, main page]

WO2010062038A2 - Composé inhibiteur de la tyrosine kinase, isomère ou sel de celui-ci acceptable pharmaceutiquement,et composition pharmaceutique le contenant - Google Patents

Composé inhibiteur de la tyrosine kinase, isomère ou sel de celui-ci acceptable pharmaceutiquement,et composition pharmaceutique le contenant Download PDF

Info

Publication number
WO2010062038A2
WO2010062038A2 PCT/KR2009/006050 KR2009006050W WO2010062038A2 WO 2010062038 A2 WO2010062038 A2 WO 2010062038A2 KR 2009006050 W KR2009006050 W KR 2009006050W WO 2010062038 A2 WO2010062038 A2 WO 2010062038A2
Authority
WO
WIPO (PCT)
Prior art keywords
isomer
tyrosine kinase
pharmaceutical composition
composition containing
same
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/KR2009/006050
Other languages
English (en)
Korean (ko)
Other versions
WO2010062038A3 (fr
Inventor
양범석
김선영
조종운
이향숙
우성호
박태교
김용주
김승태
이홍범
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Korea Institute of Science and Technology KIST
Ligachem Biosciences Inc
Original Assignee
Korea Institute of Science and Technology KIST
Legochem Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Korea Institute of Science and Technology KIST, Legochem Biosciences Inc filed Critical Korea Institute of Science and Technology KIST
Publication of WO2010062038A2 publication Critical patent/WO2010062038A2/fr
Publication of WO2010062038A3 publication Critical patent/WO2010062038A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D497/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D497/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having oxygen and sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D497/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La présente invention concerne un composé exprimé dans la formule chimique 1, un isomère de celui-ci ou un sel de celui-ci pharmaceutiquement acceptable. Le composé exprimé dans la formule chimique 1 inhibe l'activité de la tyrosine kinase du récepteur 1 à domaine discoïdine (DDR1) et du récepteur 2 à domaine discoïdine (DDR2), et peut-être ainsi utilisé valablement dans la prévention ou le traitement de maladies telles que le cancer, la cirrhose du foie, l'artériosclérose, l'arthrite rhumatoïde, l'ostéoarthrite et autre, qui sont connues pour être provoquées principalement par une activation excessive du récepteur 1 à domaine discoïdine et du récepteur 2 à domaine discoïdine.
PCT/KR2009/006050 2008-11-27 2009-10-20 Composé inhibiteur de la tyrosine kinase, isomère ou sel de celui-ci acceptable pharmaceutiquement,et composition pharmaceutique le contenant Ceased WO2010062038A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2008-0118850 2008-11-27
KR1020080118850A KR101126736B1 (ko) 2008-11-27 2008-11-27 티로신 키나아제 저해 화합물, 이의 이성질체 또는 이의 약학적으로 허용가능한 염 및 이를 포함하는 약학적 조성물

Publications (2)

Publication Number Publication Date
WO2010062038A2 true WO2010062038A2 (fr) 2010-06-03
WO2010062038A3 WO2010062038A3 (fr) 2010-07-22

Family

ID=42226201

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2009/006050 Ceased WO2010062038A2 (fr) 2008-11-27 2009-10-20 Composé inhibiteur de la tyrosine kinase, isomère ou sel de celui-ci acceptable pharmaceutiquement,et composition pharmaceutique le contenant

Country Status (2)

Country Link
KR (1) KR101126736B1 (fr)
WO (1) WO2010062038A2 (fr)

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130072482A1 (en) * 2010-05-26 2013-03-21 Beom-Seok Yang Anti-inflammatory compound having inhibitory activity against multiple tyrosine kinases and pharmaceutical composition containing same
CN103087077A (zh) * 2011-11-03 2013-05-08 上海希迈医药科技有限公司 噻吩并嘧啶和呋喃并嘧啶类衍生物、其制备方法及其在医药上的应用
WO2013068836A1 (fr) 2011-11-07 2013-05-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Antagoniste de ddr1 ou inhibiteur de l'expression génique de ddr1 destiné à être utilisé dans la prévention ou le traitement de la glomérulonéphrite rapidement progressive
JP2013538223A (ja) * 2010-09-15 2013-10-10 エフ．ホフマン−ラ ロシュ アーゲー アザベンゾチアゾール化合物、組成物及び使用方法
CN103360407A (zh) * 2012-04-10 2013-10-23 上海希迈医药科技有限公司 一种噻吩并嘧啶类衍生物、其制备方法及其在医药上的应用
JPWO2015060373A1 (ja) * 2013-10-23 2017-03-09 中外製薬株式会社 キナゾリノンおよびイソキノリノン誘導体
WO2018171726A1 (fr) * 2017-03-23 2018-09-27 高雄医学大学 Inhibiteur du récepteur 1 du domaine discoïdine, activateur et utilisation associée
WO2021239643A1 (fr) 2020-05-25 2021-12-02 Chiesi Farmaceutici S.P.A. Dérivés de benzylamine en tant qu'inhibiteurs de ddr
EP4032896A1 (fr) 2021-01-20 2022-07-27 Fundación del Sector Público Estatal Centro Nacional de Investigaciones Oncológicas Carlos III (F.S.P. CNIO) Thiazolopyrimidinones en tant qu'inhibiteurs de ddr1/2 et leurs utilisations thérapeutiques
WO2023210599A1 (fr) * 2022-04-25 2023-11-02 日本新薬株式会社 Composé servant d'inhibiteur de ddr1 kinase et médicament
US12133896B2 (en) 2017-03-23 2024-11-05 Kaohsiung Medical University Methods for treating or alleviating a bone-loss related disease or condition by administering a nucleic acid encoding a discoidin domain receptor 1 (DDR1) protein

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101540051B1 (ko) * 2013-11-27 2015-07-28 한국과학기술연구원 피부 노화 방지 또는 피부 상태 개선용 조성물

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK72996A3 (en) * 1995-06-07 1997-04-09 Pfizer Heterocyclic ring-fused pyrimidine derivatives and pharmaceutical compositions on their base
AR004010A1 (es) 1995-10-11 1998-09-30 Glaxo Group Ltd Compuestos heterociclicos
WO1999024440A1 (fr) * 1997-11-11 1999-05-20 Pfizer Products Inc. Derives de thienopyrimidine et thienopyridine utiles comme agents anticancereux
JP2005527511A (ja) * 2002-03-01 2005-09-15 ファイザー インコーポレイテッド 抗血管形成剤として有用なチエノピリジンのインドリル−尿素誘導体およびその使用法

Cited By (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130072482A1 (en) * 2010-05-26 2013-03-21 Beom-Seok Yang Anti-inflammatory compound having inhibitory activity against multiple tyrosine kinases and pharmaceutical composition containing same
US9062066B2 (en) * 2010-05-26 2015-06-23 Korea Institute Of Science And Technology Anti-inflammatory compound having inhibitory activity against multiple tyrosine kinases and pharmaceutical composition containing same
JP2013538223A (ja) * 2010-09-15 2013-10-10 エフ．ホフマン−ラ ロシュ アーゲー アザベンゾチアゾール化合物、組成物及び使用方法
US8697708B2 (en) 2010-09-15 2014-04-15 F. Hoffmann-La Roche Ag Azabenzothiazole compounds, compositions and methods of use
CN103087077A (zh) * 2011-11-03 2013-05-08 上海希迈医药科技有限公司 噻吩并嘧啶和呋喃并嘧啶类衍生物、其制备方法及其在医药上的应用
WO2013064068A1 (fr) * 2011-11-03 2013-05-10 上海希迈医药科技有限公司 Dérivés de thiénopyrimidine et de furopyrimidine, leur procédé de fabrication et leur utilisation médicale
CN103087077B (zh) * 2011-11-03 2016-05-18 上海希迈医药科技有限公司 噻吩并嘧啶和呋喃并嘧啶类衍生物、其制备方法及其在医药上的应用
WO2013068836A1 (fr) 2011-11-07 2013-05-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Antagoniste de ddr1 ou inhibiteur de l'expression génique de ddr1 destiné à être utilisé dans la prévention ou le traitement de la glomérulonéphrite rapidement progressive
CN103360407A (zh) * 2012-04-10 2013-10-23 上海希迈医药科技有限公司 一种噻吩并嘧啶类衍生物、其制备方法及其在医药上的应用
CN103360407B (zh) * 2012-04-10 2016-06-22 上海希迈医药科技有限公司 一种噻吩并嘧啶类衍生物、其制备方法及其在医药上的应用
JPWO2015060373A1 (ja) * 2013-10-23 2017-03-09 中外製薬株式会社 キナゾリノンおよびイソキノリノン誘導体
EP3061749A4 (fr) * 2013-10-23 2017-05-31 Chugai Seiyaku Kabushiki Kaisha Dérivé de quinazolinone et d'isoquinolinone
US10005739B2 (en) 2013-10-23 2018-06-26 Chugai Seiyaku Kabushiki Kaisha Quinazolinone and isoquinolinone derivative
WO2018171726A1 (fr) * 2017-03-23 2018-09-27 高雄医学大学 Inhibiteur du récepteur 1 du domaine discoïdine, activateur et utilisation associée
US10946021B2 (en) 2017-03-23 2021-03-16 Kaohsiung Medical University Methods of treating or alleviating joint diseases by administering an inhibitor of discoidin domain receptor 1 (DDR1)
US12133896B2 (en) 2017-03-23 2024-11-05 Kaohsiung Medical University Methods for treating or alleviating a bone-loss related disease or condition by administering a nucleic acid encoding a discoidin domain receptor 1 (DDR1) protein
WO2021239643A1 (fr) 2020-05-25 2021-12-02 Chiesi Farmaceutici S.P.A. Dérivés de benzylamine en tant qu'inhibiteurs de ddr
EP4032896A1 (fr) 2021-01-20 2022-07-27 Fundación del Sector Público Estatal Centro Nacional de Investigaciones Oncológicas Carlos III (F.S.P. CNIO) Thiazolopyrimidinones en tant qu'inhibiteurs de ddr1/2 et leurs utilisations thérapeutiques
WO2022157166A1 (fr) 2021-01-20 2022-07-28 Fundación Del Sector Público Estatal Centro Nacional De Investigaciones Oncológicas Carlos III (F.S.P. CNIO) Thiazolopyrimidones en tant qu'inhibiteurs de ddr1/2 et leurs utilisations thérapeutiques
WO2023210599A1 (fr) * 2022-04-25 2023-11-02 日本新薬株式会社 Composé servant d'inhibiteur de ddr1 kinase et médicament

Also Published As

Publication number Publication date
WO2010062038A3 (fr) 2010-07-22
KR20100060300A (ko) 2010-06-07
KR101126736B1 (ko) 2012-04-12

Similar Documents

Publication Publication Date Title
WO2010062038A2 (fr) Composé inhibiteur de la tyrosine kinase, isomère ou sel de celui-ci acceptable pharmaceutiquement,et composition pharmaceutique le contenant
WO2006123113A3 (fr) Composes chimiques
WO2007095124A3 (fr) Derives, compositions de benzazole et procedes d'utilisation en tant qu'inhibiteurs de la kinase aurora
WO2006106326A8 (fr) Heterocycles substitues et leur utilisation en tant qu’inhibiteurs de la chk1, de la pdk1 et de la pak
MX2009013077A (es) Derivados dde benzoxazolona.
WO2009155121A3 (fr) Inhibiteurs de la pi3 kinase
WO2008022286A3 (fr) petits inhibiteurs moléculaires de la kynurénine-3-monooxygénase
UA94622C2 (en) Kinase innhibitor
WO2006138660A3 (fr) Inhibiteurs de la sphingosine kinase
WO2011052923A3 (fr) Nouveaux composés d'indole 1,6-disubstitués utilisés en tant qu'inhibiteurs des protéines kinases
WO2009016460A3 (fr) Composés pyrazoles
NZ713361A (en) Heat shock protein binding compounds, compositions, and methods for making and using same
MX2012013197A (es) Inhibidores de indazol de cinasa.
WO2012028332A8 (fr) Composés pharmaceutiquement actifs en tant qu'inhibiteurs de axl
MY149512A (en) Pyrazolylaminopyridine derivatives useful as kinase inhibitors
WO2008021038A3 (fr) Pyridobenzazépines et méthodes d'inhibition de la progression mitotique
WO2007019251A3 (fr) Inhibiteurs de la sphingosine kinase et leurs methodes d'utilisation
WO2008118391A3 (fr) Composés qui modulent l'activité hsp90
MX2010006799A (es) Benzofuropirimidinonas como inhibidores de la proteina cinasa.
EP2617414A3 (fr) Antagonisme lissé pour le traitement de troubles liés à la voie Hedgehog
WO2010021918A8 (fr) Composés en tant qu'inhibiteurs de kinases
MX2011013325A (es) 2-(lh-pirazol-4-ilamino)-pirimidina como inhibidores de cinasa.
WO2008001195A3 (fr) Nouveaux procédés de synthèse d'inhibiteurs de dpp iv
WO2010033701A3 (fr) Inhibiteurs de la sphingosine kinase 1
PL1899329T3 (pl) Pirymidyno-podstawione pochodne benzimidazolu jako inhibitory kinaz białkowych

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09829245

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORMS 1205A DATED 03.08.11 AND 02.09.11)

122 Ep: pct application non-entry in european phase

Ref document number: 09829245

Country of ref document: EP

Kind code of ref document: A2